Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio Key International (BKYI) Current Deferred Revenue (2017 - 2025)

Bio Key International's Current Deferred Revenue history spans 13 years, with the latest figure at $659627.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 31.36% year-over-year to $659627.0; the TTM value through Sep 2025 reached $659627.0, down 31.36%, while the annual FY2024 figure was $773267.0, 86.34% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $659627.0 at Bio Key International, down from $873394.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.1 million in Q1 2025 and bottomed at $414968.0 in Q4 2023.
  • The 5-year median for Current Deferred Revenue is $660000.0 (2022), against an average of $693777.9.
  • The largest annual shift saw Current Deferred Revenue surged 86.34% in 2024 before it crashed 31.36% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $565355.0 in 2021, then fell by 8.91% to $515000.0 in 2022, then fell by 19.42% to $414968.0 in 2023, then soared by 86.34% to $773267.0 in 2024, then decreased by 14.7% to $659627.0 in 2025.
  • Per Business Quant, the three most recent readings for BKYI's Current Deferred Revenue are $659627.0 (Q3 2025), $873394.0 (Q2 2025), and $1.1 million (Q1 2025).